Nivolumab (NIVO) plus ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1

Simple item page
dc.conference.dateDEC 08-11, 2021
dc.conference.titleESMO Immuno-Oncology Congres
dc.contributor.authorReck, M.
dc.contributor.authorCiuleanu, T. E.
dc.contributor.authorPluzanski, A.
dc.contributor.authorLee, J. S.
dc.contributor.authorCaro, R. Bernabe
dc.contributor.authorLinardou, H.
dc.contributor.authorBurgers, J.
dc.contributor.authorGallardo, C.
dc.contributor.authorNishio, M.
dc.contributor.authorPeters, S.
dc.contributor.authorPaz-Ares, L. G.
dc.contributor.authorHellmann, M. D.
dc.contributor.authorBorghaei, H.
dc.contributor.authorRamalingam, S. S.
dc.contributor.authorO'Byrne, K.
dc.contributor.authorHu, N.
dc.contributor.authorBushong, J.
dc.contributor.authorEccles, L.
dc.contributor.authorGrootendorst, D.
dc.contributor.authorBrahmer, J. R.
dc.contributor.authoraffiliation[Reck, M.] German Ctr Lung Res DZL, Dept Thorac Oncol, Airway Res Ctr North ARCN, LungenClin, Grosshansdorf, Germany
dc.contributor.authoraffiliation[Ciuleanu, T. E.] Univ Med & Pharm Iuliu Hatieganu, Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania
dc.contributor.authoraffiliation[Pluzanski, A.] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Lung Canc & Chest Tumours, Warsaw, Poland
dc.contributor.authoraffiliation[Lee, J. S.] Seoul Natl Univ, Bundang Hosp, Dept Hematol Oncol, Seongnam, South Korea
dc.contributor.authoraffiliation[Caro, R. Bernabe] Inst Biomed Sevilla, Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Linardou, H.] Metropolitan Hosp, Dept Oncol 4, Athens, Greece
dc.contributor.authoraffiliation[Linardou, H.] Metropolitan Hosp, Comprehens Clin Trials Ctr, Athens, Greece
dc.contributor.authoraffiliation[Burgers, J.] Antoni van Leeuwenhoek Hosp, Dept Thorac Oncol, Netherlands Canc Inst, Amsterdam, Netherlands
dc.contributor.authoraffiliation[Gallardo, C.] Inst Oncol Fdn Arturo Lopez Perez, Dept Oncol, Santiago, Chile
dc.contributor.authoraffiliation[Nishio, M.] Canc Inst Hosp Japanese Fdn Canc Res, Dept Thorac Med Oncol, Tokyo, Japan
dc.contributor.authoraffiliation[Peters, S.] Lausanne Univ Hosp, Dept Oncol, Lausanne, Switzerland
dc.contributor.authoraffiliation[Paz-Ares, L. G.] Univ Complutense, Hosp Univ 12 Octubre, Lung Canc Clin Res Unit CNIO H12o, Madrid, Spain
dc.contributor.authoraffiliation[Paz-Ares, L. G.] CiberOnc, Madrid, Spain
dc.contributor.authoraffiliation[Hellmann, M. D.] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA
dc.contributor.authoraffiliation[Borghaei, H.] Fox Chase Canc Ctr, Dept Hematol & Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
dc.contributor.authoraffiliation[Ramalingam, S. S.] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA
dc.contributor.authoraffiliation[O'Byrne, K.] Queensland Univ Technol, Translat Res Inst, Princess Alexandra Hosp, Brisbane, Qld, Australia
dc.contributor.authoraffiliation[Hu, N.] Bristol Myers Squibb, Biostat, Princeton, NJ USA
dc.contributor.authoraffiliation[Bushong, J.] Bristol Myers Squibb, Dept Global Drug Dev, Princeton, NJ USA
dc.contributor.authoraffiliation[Eccles, L.] Bristol Myers Squibb, WW Med Oncol Lung Canc, Princeton, NJ USA
dc.contributor.authoraffiliation[Grootendorst, D.] Bristol Myers Squibb, Oncol Imaging, Princeton, NJ USA
dc.contributor.authoraffiliation[Brahmer, J. R.] Johns Hopkins Kimmel Canc Ctr, Dept Oncol, Baltimore, MD USA
dc.contributor.funderBristol Myers Squibb
dc.date.accessioned2025-01-07T16:39:24Z
dc.date.available2025-01-07T16:39:24Z
dc.date.issued2021-12-10
dc.identifier.doi10.1016/j.annonc.2021.10.141
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753421046779/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27921
dc.identifier.wosID731051400125
dc.issue.number7
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS1430-S1431
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleNivolumab (NIVO) plus ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

Instituto de Investigación Biomédica de Sevilla (IBIS)
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía